Last reviewed · How we verify
sodium chloride (7%)
Sodium chloride 7% is a hypertonic saline solution that draws fluid from cells and tissues into the vascular space through osmotic pressure.
Sodium chloride 7% is a hypertonic saline solution that draws fluid from cells and tissues into the vascular space through osmotic pressure. Used for Cerebral edema and elevated intracranial pressure, Hyponatremia (severe symptomatic), Traumatic brain injury.
At a glance
| Generic name | sodium chloride (7%) |
|---|---|
| Also known as | Hyper-Sal, Hypertonic saline (7%) |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Hypertonic saline solution |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Neurology |
| Phase | FDA-approved |
Mechanism of action
The high concentration of sodium chloride creates an osmotic gradient that pulls intracellular and interstitial fluid into the bloodstream, increasing circulating volume and reducing cellular edema. This mechanism is particularly useful in treating cerebral edema and raised intracranial pressure by reducing brain cell swelling. The solution also has mild anti-inflammatory properties and may improve microcirculatory flow.
Approved indications
- Cerebral edema and elevated intracranial pressure
- Hyponatremia (severe symptomatic)
- Traumatic brain injury
Common side effects
- Hypernatremia
- Phlebitis at infusion site
- Hyperchloremic acidosis
- Renal dysfunction
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (PHASE1)
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (PHASE1)
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sodium chloride (7%) CI brief — competitive landscape report
- sodium chloride (7%) updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI